Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $416.1 million.

  • Rhythm Pharmaceuticals' Cash & Equivalents rose 76718.21% to $416.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $416.1 million, marking a year-over-year increase of 76718.21%. This contributed to the annual value of $89.6 million for FY2024, which is 4832.39% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Cash & Equivalents stood at $416.1 million, which was up 76718.21% from $291.0 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Cash & Equivalents registered a high of $416.1 million during Q3 2025, and its lowest value of $48.0 million during Q3 2024.
  • Over the past 5 years, Rhythm Pharmaceuticals' median Cash & Equivalents value was $92.7 million (recorded in 2021), while the average stood at $133.8 million.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Cash & Equivalents crashed by 6498.61% in 2023 and then surged by 76718.21% in 2025.
  • Rhythm Pharmaceuticals' Cash & Equivalents (Quarter) stood at $59.6 million in 2021, then soared by 114.86% to $128.0 million in 2022, then plummeted by 52.81% to $60.4 million in 2023, then skyrocketed by 48.32% to $89.6 million in 2024, then skyrocketed by 364.39% to $416.1 million in 2025.
  • Its Cash & Equivalents stands at $416.1 million for Q3 2025, versus $291.0 million for Q2 2025 and $314.5 million for Q1 2025.